Medical procurement in 2026 looks different from medical procurement in 2020. Regulatory pathways have tightened (EU MDR / IVDR are fully in force, UKCA marking is active, FDA continues to expand pre-market scrutiny), supplier resilience has become a board-level concern after the supply-shocks of 2020–2023, and digital procurement tooling has matured. This guide walks through the modern medical procurement workflow as we run it.
Step one is specification. A good procurement engagement starts with a written brief that captures the clinical requirement, the technical specification, the regulatory pathway in the destination market, and the commercial envelope. Without that brief, supplier responses are not comparable and decisions become opinion-based. We require a signed brief before any sourcing work begins — and we recommend the same discipline whether you outsource procurement or run it in-house.
Step two is sourcing strategy: make / buy / refurbish; single-origin or multi-origin; competitive RFQ or sole-source. The right answer depends on the category, the timeline, the volume, and the destination market. There is no universal rule.
Step three is the RFQ itself. Modern RFQs run against shortlisted, pre-qualified suppliers — not open-ended invitations. Responses are scored against documented acceptance criteria, not against gut feel.
Step four is regulatory pre-clearance. The single biggest source of avoidable delay in international procurement is regulatory documentation arriving wrong, late, or in the wrong format. Pre-clearance against the destination-market requirement before cargo leaves origin is the highest-leverage intervention in the workflow.
Step five is execution: production tracking, FAT for capital equipment, freight, customs, delivered installation, training, and warranty hand-off. Each step has named accountability against agreed milestones.
The buyers who get the most out of modern medical procurement are the ones who treat it as a discipline — documented, repeatable, audit-trail-generating — rather than as a series of opportunistic transactions. The cost difference compounds across every purchase.